The HDAC2 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human liver adenocarcinoma cell line, in which the HDAC2 gene has been disrupted through targeted genome editing. This polyclonal product provides a heterogeneous pool carrying diverse HDAC2 loss-of-function mutations, enabling robust functional studies without the constraints of clonal selection. It is particularly suited for large-scale screens and pooled functional assays, offering a versatile model for investigating HDAC2-dependent epigenetic regulation in hepatocellular carcinoma contexts.
SK-HEP-1 cells were originally established from the ascitic fluid of a patient with liver adenocarcinoma and exhibit an epithelial morphology characteristic of hepatocellular carcinoma cells. As a widely used hepatic cancer model, these cells are employed to study proliferation, apoptosis, and metastatic dissemination, and they efficiently form tumors in xenograft models. Their origin from a metastatic site and their epithelial nature make them a clinically relevant system for examining the role of HDAC2 in advanced liver cancer progression.
HDAC2 (histone deacetylase 2) is a class I enzyme that catalyzes the removal of acetyl groups from histone lysine residues, leading to chromatin condensation and transcriptional repression. It functions within multi-subunit corepressor complexes including the SIN3A-HDAC2 complex, the NuRD complex (incorporating MTA2, MBD2, and CHD4), and the CoREST complex, where it interacts with transcriptional regulators such as Rb, NCOR1, and Sin3A. HDAC2 activity is modulated by upstream signals from p53, Sp1, MYC, HIF1A, protein kinase CK2, and E2F1, and it governs downstream effectors like p21 (CDKN1A), BIM (BCL2L11), and E-cadherin (CDH1). Through deacetylation of histones and non-histone substrates, HDAC2 represses tumor suppressor genes, thereby promoting cell cycle progression, survival, and epithelial?Cmesenchymal transition, with overexpression commonly driving hepatocarcinogenesis and metastasis.
In the SK-HEP-1 hepatocellular carcinoma model, HDAC2 knockout permits direct interrogation of the epigenetic mechanisms underlying liver tumorigenesis and metastatic potential. Loss of HDAC2 function relieves transcriptional repression of p21 and BIM, potentially restoring checkpoint control and apoptotic pathways often subverted in cancer. The p53-p21 axis and the E2F-Rb pathway can be systematically dissected to uncover vulnerabilities to HDAC inhibitor therapies. Consequently, this knockout model helps elucidate how HDAC2-mediated chromatin remodeling influences hepatocellular carcinoma cell behavior and provides a platform for therapeutic targeting of epigenetic regulators.
This HDAC2 knockout polyclonal cell product is designed for diverse research applications, including functional characterization of HDAC2 in liver cancer, epigenetic screening via histone acetylation analysis, and mechanism-of-action studies for HDAC inhibitor development. Representative assays encompass Western blotting and RT-qPCR for knockout validation and target expression profiling, ChIP-qPCR for chromatin modification mapping, immunofluorescence for epigenetic mark localization, and flow cytometry for cell cycle and apoptosis assessment. Additional functional analyses such as colony formation assays, Transwell migration and invasion assays, and drug sensitivity testing with HDAC inhibitors enable comprehensive phenotypic evaluation. The polyclonal population is ready for expansion and immediate experimental use. For further information, please contact Ascent Research.
